Abstract: A safety housing based implant/medicament injecting system. System includes a needle assembly prefilled implant/medicament for injection and an injecting needle/cannula, a housing for accommodating the needle assembly under usual bias inside said housing, a plunger means having a plunger rod configured for stage wise forward motion including an initial injecting plunger forward motion with the needle assembly within the housing to first engage the needle assembly with the housing and subsequent continuing injecting plunger forward motion independent of the needle assembly for injecting of the implant/medicament, and post injecting return of the needle assembly secured inside said housing blocking any subsequent use thereof.

Abstract: A safety housing based implant/medicament injecting system. System includes a needle assembly prefilled implant/medicament for injection and an injecting needle/cannula, a housing for accommodating the needle assembly under usual bias inside said housing, a plunger means having a plunger rod configured for stage wise forward motion including an initial injecting plunger forward motion with the needle assembly within the housing to first engage the needle assembly with the housing and subsequent continuing injecting plunger forward motion independent of the needle assembly for injecting of the implant/medicament, and post injecting return of the needle assembly secured inside said housing blocking any subsequent use thereof.

Abstract: A safety housing based implant/medicament injecting system. System includes a needle assembly prefilled implant/medicament for injection and an injecting needle/cannula, a housing for accommodating the needle assembly under usual bias inside said housing, a plunger means having a plunger rod configured for stage wise forward motion including an initial injecting plunger forward motion with the needle assembly within the housing to first engage the needle assembly with the housing and subsequent continuing injecting plunger forward motion independent of the needle assembly for injecting of the implant/medicament, and post injecting return of the needle assembly secured inside said housing blocking any subsequent use thereof.

Abstract: A safety housing based implant/medicament injecting system. System includes a needle assembly prefilled implant/medicament for injection and an injecting needle/cannula, a housing for accommodating the needle assembly under usual bias inside said housing, a plunger means having a plunger rod configured for stage wise forward motion including an initial injecting plunger forward motion with the needle assembly within the housing to first engage the needle assembly with the housing and subsequent continuing injecting plunger forward motion independent of the needle assembly for injecting of the implant/medicament, and post injecting return of the needle assembly secured inside said housing blocking any subsequent use thereof.

Abstract: A safety housing based implant/medicament injecting system. System includes a needle assembly prefilled implant/medicament for injection and an injecting needle/cannula, a housing for accommodating the needle assembly under usual bias inside said housing, a plunger means having a plunger rod configured for stage wise forward motion including an initial injecting plunger forward motion with the needle assembly within the housing to first engage the needle assembly with the housing and subsequent continuing injecting plunger forward motion independent of the needle assembly for injecting of the implant/medicament, and post injecting return of the needle assembly secured inside said housing blocking any subsequent use thereof.

Abstract: The present invention provides a long circulating non-pegylated liposomal doxorubicin hydrochloride composition for parenteral administration and a process for its preparation. The circulation time in Swiss albino mice is at least 25 times longer than conventional non-liposomal formulations. The non-pegylated liposomes are stable, exhibit low toxicity and have been found to be efficacious in different tumor models.

Abstract: The present invention provides a long circulating non-pegylated liposomal doxorubicin hydrochloride composition for parenteral administration and a process for its preparation. The circulation time in Swiss albino mice is at least 25 times longer than conventional non-liposomal formulations. The non-pegylated liposomes are stable, exhibit low toxicity and have been found to be efficacious in different tumor models.

Abstract: The invention discloses a stable intravenous Propofol oil-in-water emulsion composition having mixed preservatives of low toxicity that is capable of withstanding accidental contamination of bacteria and fungi. The preservative system employed comprising of monoglyceryl ester of lauric acid (Monolaurin) and a member selected from (a) capric acid and/or its soluble alkaline salts or its monoglyceryl ester (Monocaprin); (b) edetate; and (c) capric acid and/or its soluble alkaline salts or its monoglyceryl ester (Monocaprin) and edetate.

Abstract: Anti-RhD monoclonal antibodies and methods for the production thereof.

Abstract: The present invention describes Stable injectable oil-in-water Docetaxel nanoemulsion composition having Docetaxel concentrations as high as 20 mg/ml, devoid of hypersensitivity reaction and fluid retention. It employs Synthetic triglycerides, and DSPE PEG-2000, Natural phosphatides, Polyhydric alcohol and Water for injection. In another embodiment lyophilised products with added Cryoprotectants have been described which on reconstitution gives nanoemulsion suitable for parenteral administration.

Abstract: The present invention provides a long circulating non-pegylated liposomal doxorubicin hydrochloride composition for parenteral administration and a process for its preparation. The circulation time in Swiss albino mice is at least 25 times longer than conventional non-liposomal formulations. The non-pegylated liposomes are stable, exhibit low toxicity and have been found to be efficacious in different tumor models.

Abstract: The present invention provides aqueous Ifosfamide compositions and a process for their preparation, in which the compositions have a reduced toxicity over and above the concomitant use of the uroprotective agent, Mesna. Aqueous Ifosfamide compositions can be prepared at concentrations as high has 1,1000 mg/ml.

Abstract: The present invention provides a long circulating non-pegylated liposomal doxorubicin hydrochloride composition for parenteral administration and a process for its preparation. The circulation time in Swiss albino mice is at least 25 times longer than conventional non-liposomal formulations. The non-pegylated liposomes are stable, exhibit low toxicity and have been found to be efficacious in different tumor models.

Abstract: The present invention provides aqueous Ifosfamide compositions and a process for their preparation, in which the compositions have a reduced toxicity over and above the concomitant use of the uroprotective agent, Mesna. Aqueous Ifosfamide compositions can be prepared at concentrations as high has 1,1000 mg/ml.